## CLAIMS

1. A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt thereof, which peptide has the sequence

pyroGlu-His-Trp-Ser-Xaa1-Gly-Xaa2/Xaa3-Pro-Gly-NH2

wherein Xaa1 is His or Tyr,

Xaaz is Trp or Leu, and

Xaa3 is Tyr or Arg,

provided that when Xaa1 is Tyr and Xaa2 is Leu, then Xaa3 is not Arg,

and which formulation further comprises a pharmaceutically acceptable biodegradable polymer.

- 2. The pharmaceutical composition according to Claim 1, wherein the peptide is pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub>
- 3. The formulation according to Claim 1, wherein the polymer is a polymer of a hydroxy derivative of a carboxylic acid, or a copolymer of such derivatives.
- 4. The formulation according to Claim 3, wherein the polymer is a polymer of glycolic acid, a polymer of lactic acid, or a copolymer of lactic and glycolic acids.
- 5. The formulation according to Claim 1 wherein the peptide is microencapsulated by the polymer.
- 6. A method for the treatment of a human medical condition, which method comprises the administration to an individual in need of such treatment of a therapeutically effective amount of a controlled release formulation of a peptide according to any of the preceding Claims.




specs\40325pct.2000

TU,

- A formulation according to any of claims 1 to 5 for treatment of or for protection against disorder of bone growth or disorder of prostate growth.
- The use of a peptide or salt as defined in claim 1 or 2, together with a pharmaceutically acceptable biodegradable polymer, for the preparation of a controlled release medicament for the treatment of or protection against disorder of bone growth or disorder of prostate growth.
- 9. A use according to claim 8 wherein said polymer is
- [a] a polymer of a hydroxy derivative of a carboxylic acid, or a co-polymer of such derivatives, or
- [b] a polymer of glycolic acid, a polymer of lactic acid, or a co-polymer of lactic and glycolic acids.
- A use according to claim 8 or 9 wherein said disorder is selected from age-10. related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and/secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, glucocorticoid-related osteoporosis, benign prostatic hyperplasia and prostate cancer.
- 11. A formulation according to claim Z for the treatment of or protection against disorder selected from age-related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, glucocorticoid-related osteoporosis, benign prostatic hyperplasia and prostate cancer.

16

AMENDED SHEET



specs\40325pct.2000



ş.h

Į.k H

ļ.

the the thick

12. A method for treating or protecting against a human disorder of bone growth or of prostate growth, which method comprises the administration to an individual in need of such treatment or protection of a therapeutically effective amount on a formulation according to any of claims 1 to 5.

PEDI: 99958357.8 - G899/04045

13. A method according to claim 12 wherein said disorder is selected from agerelated osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, glucocorticoid-related osteoporosis, benign prostatic hyperplasia and prostate cancer.

AMENDED SHEET